mTOR pathway and mTOR inhibitors in cancer therapy
著者
書誌事項
mTOR pathway and mTOR inhibitors in cancer therapy
(Cancer drug discovery and development)
Humana Press, c2010
大学図書館所蔵 全1件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographical references and index
内容説明・目次
内容説明
The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment - targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. In mammalian cells, mTOR exists in at least two multi-protein complexes that have critical roles in regulating cellular homeostasis and survival. As with many other areas of science, discovery of TOR signaling was fortuitous. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island). Rapamycin was rst discovered to be a potent antifungal agent and next as an immune suppressive drug. It was only later that it was found to be active as an antitumor agent in non-clinical models; although it was not developed for this indication. The history of rapamycin presents one of the rst examples of chemical genetics.
目次
1. N. Kubica and J. Blenis "mTORC1: A signaling integration node involved in cell growth"
2. Z. Feng and A.J. Levine "The Regulation of the IGF-1/mTOR Pathway by the p53 Tumor Suppressor Gene Functions"
3. H. Mead, M. Zeremski and M. Guba "mTOR Signaling in Angiogenesis"
4. J. Brugaroles "mTOR signaling and hypoxia"
5. D. Akhavan and P.S. Mischel "mTOR signaling in Glioblastoma: Lessons learned from bench to bedside"
6. P. Houghton "mTOR and cancer therapy: General Principles"
7. S. Faivre, T. Decaens and E. Raymond "mTOR and cancer therapy: Clinical development and novel prospects"
8. M. Breuleux and H. Lane "Drug combinations as a therapeutic approach for mTORC1 inhibitors in human cancer"
9. B. D. Fonseca and C.G. Proud "Downstream targets of mTORC1"
10. R. J. O. Dowling and N. Sonenberg "Downstream of mTOR: Translational control of cancer"
11. O. Larsson and P.B. Bitterman "Genome-wide analysis of translational control"
12. P.B. Bitterman and V.A. Polunovsky "Translational Control of Cancer: Implications for Targeted Therapy"
13. J. Pelletier and J.R. Graff "Downstream from mTOR: Therapeutic Approaches to targeting the eIF4F translation initiation complex"
「Nielsen BookData」 より